Targeting DNA methyltransferases for cancer therapy

Area of Science:

• Epigenetics and Molecular Oncology

Background:

• DNA methyltransferases (DNMTs) are key regulators of genomic DNA methylation in mammals.
• Aberrant DNMT function, characterized by hypomethylation and hypermethylation of tumor suppressor genes (TSGs), is linked to cancer progression and treatment resistance.

Purpose of the Study:

• To review the therapeutic effects of DNMT inhibitors in cancer treatment.
• To explore the potential of developing novel DNMT inhibitors with enhanced activity, selectivity, and drug-like properties.

Main Methods:

• Literature review of studies on DNMT inhibitors and their therapeutic applications in oncology.
• Analysis of current FDA and EMA-approved DNMT inhibitors and their mechanisms.

Main Results:

• Nucleoside DNMT inhibitors like Azacytidine and Decitabine are approved for treating hematological malignancies such as AML, CMML, and MDS.
• Targeting DNMTs represents a highly promising strategy for anti-cancer therapy.

Conclusions:

• DNMT inhibitors demonstrate significant therapeutic potential in treating various cancers.
• Further research into novel DNMT inhibitors is essential for advancing cancer treatment options.